Beam Therapeutics Doses First Patient in BEAM-302 Pivotal Cohort
Beam Therapeutics dosed the first participant in the global pivotal cohort of BEAM-302, an in vivo liver-directed base-editing therapy for alpha-1 antitrypsin deficiency. The cohort is embedded in the ongoing open-label Phase I/II study…
